|
| 36342789 | Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. | Circulation | 2023 |
| 36303404 | Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. | Eur Heart J | 2023 |
| 36342789 | Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. | Circulation | 2023 |
| 36074222 | MicroRNA-375 repression of Kruppel-like factor 5 improves angiogenesis in diabetic critical limb ischemia. | Angiogenesis | 2023 |
| 35980763 | A polygenic risk score predicts atrial fibrillation in cardiovascular disease. | Eur Heart J | 2023 |
| 36399721 | Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. | Diabetes Care | 2023 |
| 37606673 | Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. | JAMA | 2023 |
| 37913509 | Encased in Peril. | N Engl J Med | 2023 |
| 37886880 | Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. | Circ Heart Fail | 2023 |
| 37634707 | Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. | J Am Coll Cardiol | 2023 |
| 37556796 | Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. | Diabetes Care | 2023 |
| 37610398 | Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 36779348 | Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE. | Circulation | 2023 |
| 36592046 | IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. | JACC Heart Fail | 2023 |
| 37407113 | Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37344040 | Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. | J Am Coll Cardiol | 2023 |
| 36576811 | Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention. | JAMA Cardiol | 2023 |
| 36821386 | A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia. | JCI Insight | 2023 |
| 36881399 | Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum. | JACC Heart Fail | 2023 |
| 36493607 | Clinical Significance of Culprit Vessel Occlusion in Patients With Non-ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. | Am J Cardiol | 2023 |
| 36878239 | Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. | Lancet Diabetes Endocrinol | 2023 |
| 36811901 | Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER. | JAMA Cardiol | 2023 |
| 37318419 | Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2023 |
| 37256598 | Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials. | JAMA Cardiol | 2023 |
| 37068132 | Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease". | Circulation | 2023 |
| 36691960 | Response to Mei et al. regarding the incidence and predictors of hospitalization for heart failure among patients with stable atherosclerosis in the TRA 2°P-TIMI 50 trial. | Clin Cardiol | 2023 |
| 37358785 | Stroke in patients with heart failure and reduced or preserved ejection fraction. | Eur Heart J | 2023 |
| 36857035 | Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. | JAMA Cardiol | 2023 |
| 37039015 | Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. | Circulation | 2023 |
| 37220172 | Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. | Eur Heart J | 2023 |
| 37097749 | Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis. | JCI Insight | 2023 |
| 36720377 | Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. | Vascul Pharmacol | 2023 |
| 37634707 | Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function. | J Am Coll Cardiol | 2023 |
| 37913509 | Encased in Peril. | N Engl J Med | 2023 |
| 37556796 | Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. | Diabetes Care | 2023 |
| 37886880 | Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. | Circ Heart Fail | 2023 |
| 37610398 | Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37606673 | Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. | JAMA | 2023 |
| 37256598 | Percutaneous Coronary Intervention vs Coronary Artery Bypass Graft Surgery for Left Main Disease in Patients With and Without Acute Coronary Syndromes: A Pooled Analysis of 4 Randomized Clinical Trials. | JAMA Cardiol | 2023 |
| 37220172 | Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. | Eur Heart J | 2023 |
| 37318419 | Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. | JACC Heart Fail | 2023 |
| 37344040 | Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus. | J Am Coll Cardiol | 2023 |
| 37407113 | Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. | J Am Coll Cardiol | 2023 |
| 37039015 | Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. | Circulation | 2023 |
| 37097749 | Impaired angiogenesis in diabetic critical limb ischemia is mediated by a miR-130b/INHBA signaling axis. | JCI Insight | 2023 |
| 37068132 | Response by O'Donoghue et al to Letter Regarding Article, "Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease". | Circulation | 2023 |
| 37358785 | Stroke in patients with heart failure and reduced or preserved ejection fraction. | Eur Heart J | 2023 |
| 36821386 | A miRNA/CXCR4 signaling axis impairs monopoiesis and angiogenesis in diabetic critical limb ischemia. | JCI Insight | 2023 |
| 36592046 | IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. | JACC Heart Fail | 2023 |
| 36857035 | Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial. | JAMA Cardiol | 2023 |